15/01/2024, 09:16 Viatris In 2024 May Be The Most Polarising Investment Opportunity In Pharma (VTRS) _ Seeking Alpha
Home Healthcare
Viatris In 2024 May Be The Most Polarising
Investment Opportunity In Pharma
Jan. 14, 2024 8:04 AM ET | Viatris Inc. (VTRS) Stock | 23 Comments | 13 Likes
Edmund Ingham
Investing Group Leader
Summary
Viatris stock has been on the rise, up over 20% in the past month, reaching its highest
price since February 2023.
The company's revenues are derived from established brands, generics, and complex
generics, with a significant portion coming from patent expired drugs.
Viatris faces challenges in growing its generics business to offset declining revenues and
is heavily indebted, which may impact its profitability and value proposition.
Viatris is a tough business to value - shares are seemingly cheap, until you consider the
shrinking top line revenues, and ~$17bn of debt.
This could be one of the toughest investment decisions in Pharma - I am prepared to hold
long term to see how things pan out, but the risks around such a strategy need to be
highlighted. Management could send the business into a tailspin.
https://seekingalpha.com/article/4662767-viatris-2024-may-be-polarising-investment-opportunity-pharma?mailingid=33999913&messageid=mus… 1/11
15/01/2024, 09:16 Viatris In 2024 May Be The Most Polarising Investment Opportunity In Pharma (VTRS) _ Seeking Alpha
PM Images
Investment Overview - Viatris A Pharma Of Global Significance
Shares in Viatris (NASDAQ:VTRS), the company formed in 2020 via a merger between New
York Pharma giant Pfizer's (PFE) Upjohn legacy asset division, and Netherlands
headquartered generic drug giant Mylan, have been on the rise in recent weeks - up >20%
across the past month. Current traded price is $12 per share, the highest price since February
2023.
Viatris stock was worth ~$16 per share post listing in November 2020, so investors who have
been holding shares long-term are down ~25%, although Viatris' dividend of $0.12 per quarter,
or $0.48 per annum, provides some comfort, yielding ~4% per annum presently.
https://seekingalpha.com/article/4662767-viatris-2024-may-be-polarising-investment-opportunity-pharma?mailingid=33999913&messageid=mus… 2/11
15/01/2024, 09:16 Viatris In 2024 May Be The Most Polarising Investment Opportunity In Pharma (VTRS) _ Seeking Alpha
~64% of Viatris's revenues, which are expected to reach $15.4 - $15.6bn in 2023, are derived
from its established brands / Upjohn division, which includes patent expired drugs such as
Viagra, Lyrica, Lipitor, Celebrex, and Epi Pen, with 32% coming from the generics business,
and 4% from the "Complex Generics ("Gx") business.
In total, Viatris markets and sells >1,400 approved molecules, manufactured at 40 different
sites globally. ~34% of the company's business is in Europe, 26% in the US, 17% in emerging
markets, 14% in Greater China, and 9% in Japan, Australia and New Zealand (the "JANZ"
region).
Is Viatris Stock Expensive Or Cheap? Smoke and Mirrors
Valuation Disguises Some Unsettling Truths
At first glance, it is hard escape the conclusion that Viatris stock is exceptionally cheap. For
example, Viatris' market cap - presently $14.3bn - is lower than its forecast revenue for 2023 of
$15.5bn, giving the company a price to sales ("P/S") ratio of <1x. This is a rare phenomenon
which is often interpreted as a sign of a company being undervalued, or, as a potential red flag
- if the valuation is so low, there must be hidden problems at the company.
Viatris is also a profitable company - as the company's CEO Scott Smith, formerly President
and Chief Operating Officer at Celgene Corporation, pointed out via a presentation given
during a fireside chat at the JP Morgan Healthcare conference this week, the company has
generated ~$7.2bn of free cash flow across the past 11 quarters, and expects to generate
~$2.3bn of annual free cash flow going forward.
If the company's top and bottom line performance is strong, as Viatris' appears to be, then,
again, it would suggest the company is either substantially undervalued, representing a
"screaming buy" opportunity (as I concluded back in June 2021, in a note for Seeking Alpha),
or that there may be some hidden underlying issues undermining a higher valuation.
The two most important issues to consider in this respect are firstly, that top line revenues are
shrinking, and secondly, that the company is heavily indebted.
Ultimately, there was a good reason Pfizer was willing to offload its UpJohn business, and that
reason is that the entire division consists of older drugs, with no patent protection, whose
revenue contributions were in terminal decline owing to generic competition, new and better
drugs, and less emphasis on marketing older drugs.
Viatris' biggest challenge is to grow its own generics and complex generics businesses fast
enough to offset falling revenues within the established brands division, to make sure the
business does not shrink, given shareholders generally see shrinking revenues as a red flag.
https://seekingalpha.com/article/4662767-viatris-2024-may-be-polarising-investment-opportunity-pharma?mailingid=33999913&messageid=mus… 3/11
15/01/2024, 09:16 Viatris In 2024 May Be The Most Polarising Investment Opportunity In Pharma (VTRS) _ Seeking Alpha
Unfortunately, Viatris' revenues were $17.8bn in 2021, $16.2bn in 2022, and are forecast to be
$15.5bn in 2023 - this helps to explain why the share price has been falling - Viatris' valuation
is tracking its declining sales, and will likely continue to do so, until the situation can be
reversed.
At the same time, Viatris reported a long term debt position of $17.1bn as of Q3 2023, plus a
current portion of long term debt of $1.3bn. Unfortunately, with paying down debt being an
urgent priority for the company, which needs to maintain its investment grade rating and avoid
a damaging (for the share price and business) downgrade, Viatris has substantially less cash
to reinvest into its business than might be expected.
https://seekingalpha.com/article/4662767-viatris-2024-may-be-polarising-investment-opportunity-pharma?mailingid=33999913&messageid=mus… 4/11
15/01/2024, 09:16 Viatris In 2024 May Be The Most Polarising Investment Opportunity In Pharma (VTRS) _ Seeking Alpha
Viatris debt schedule (Q3 10Q submission)
https://seekingalpha.com/article/4662767-viatris-2024-may-be-polarising-investment-opportunity-pharma?mailingid=33999913&messageid=mus… 5/11
15/01/2024, 09:16 Viatris In 2024 May Be The Most Polarising Investment Opportunity In Pharma (VTRS) _ Seeking Alpha
Reviewing Viatris' debt schedule, it strikes me that the interest rate on most of the debt is not
too onerous - the company chose the right time to take on debt, when interest rates were low,
and may reap some benefit from that in the coming months and years, as interest rates are
expected to rise, which will make Viatris debt look cheap. This may explain why Viatris' share
price has been rising in recent weeks.
Nevertheless, >$17bn of debt is ultimately going to weigh heavily on a company Viatris' size,
and restrict its profitability, and the value proposition for investors. As Fitch Ratings discusses
it:
Viatris' 'BBB' rating reflects the company's global scale and diversification by product and
geography, diverse pipeline of new products and commitment to debt reduction. However,
revenue growth challenges, restructuring costs and pricing pressures offset these strengths.
Following its sale of selected assets, Fitch anticipates Viatris will prioritize debt reduction to
sustain its EBITDA leverage at or below 3.5x and FCF/debt at or above 10%.
In fact, in its JPM conference presentation Viatris states it expects to generate ~$2.3bn of
annual cash flow going forward, and expects to invest 50% of this figure into the business, and
return 50% to shareholders via quarterly dividends and share buybacks.
The fact that Viatris is effectively guaranteeing its profitability long-term can only be a good sign
for investors, but on the more negative side, there is no guarantee the business will grow in
size.
Viatris' Shrinking Pains - How The Company Plans To Rejuvenate
Its Product Portfolio
Clearly, it is not going to be easy for Viatris to uncover a new Viagra, Lyrica, or Liptor - best-in-
class drugs that still make annual sales in the triple-digit millions years after their patent
protections have elapsed - and in fact, Viatris has done more trimming of its portfolio than
adding to it since becoming a stand-alone company.
In 2022, Viatris agreed to sell its biosimilars business - regarded at the time as the crown jewel
of its business in terms of future revenue potential - to Biocon Biologics. Admittedly, Viatris
owns a ~13% share of Biocon, but when the deal was first announced, Viatris stock fell from
~$15, to ~$10 overnight, suggesting that investors wanted to see the business grow, not
shrink.
Unfortunately, there will be further business divestitures in 2024 - as per Viatris' Q3 2023
quarterly report / 10Q submission:
https://seekingalpha.com/article/4662767-viatris-2024-may-be-polarising-investment-opportunity-pharma?mailingid=33999913&messageid=mus… 6/11
15/01/2024, 09:16 Viatris In 2024 May Be The Most Polarising Investment Opportunity In Pharma (VTRS) _ Seeking Alpha
On October 1, 2023, the Company announced it received an offer for the divestiture of
substantially all of its OTC business, and entered into definitive agreements to divest its
women’s healthcare business and, separately, in another transaction, its rights to two
women’s healthcare products, its API business in India and commercialization rights in the
Upjohn Distributor Markets. The transactions are expected to close by the end of the first
half of 2024
Simply put, it is hard to get excited about a company that is $17bn in debt, and selling off its
assets, even if that company is trading at a P/S ratio of <1x, and paying a dividend of 4%.
Clearly, the company is not about to go on an M&A spree, or attempt to develop its own
molecules in-house, which is the preferred strategy for Big Pharma. Developing new drugs with
lengthy periods of patent protection is considered the most lucrative and profitable way to win
in the Big Pharma field - and explains why, besides Pfizer, Merck & Co (MRK), GSK (GSK),
Johnson & Johnson (JNJ), and Sanofi (SNY) have all spun out older business divisions into
new business entities - shedding their dead wood, and their debt, while realising significant tax
benefits - Merck, for example, paid itself an $8bn tax free dividend after spinning out its
generics / women's health businesses into a new entity, Organon (OGN), in 2021.
Viatris' solution to its shrinking business has been to identify three markets where it feels it can
make strategic, and ultimately financial, headway - eye care, dermatology, and
gastroenterology. Eye care is the most established business to date, thanks to the approval of
Tyrvaya - the dry eye disease therapy acquired via Viatris' $425m acquisition of Ophthalmology
specialist Oyster Point last year - a rare case of Viatris using M&A to bolster its business.
Management has suggested that Eye Care could be a $1bn revenue business by 2028, with
three other assets at the Phase 3 clinical study stage, and that complex injectables can make a
>$1bn contribution to the top line by 2027, and if we look at some of the products Viatris is
aiming to bring to market, there are plenty of opportunities.
https://seekingalpha.com/article/4662767-viatris-2024-may-be-polarising-investment-opportunity-pharma?mailingid=33999913&messageid=mus… 7/11
15/01/2024, 09:16 Viatris In 2024 May Be The Most Polarising Investment Opportunity In Pharma (VTRS) _ Seeking Alpha
Viatris pipeline - complex generics (Viatris Q3 2023 earnings presentation )
For example, Viatris is already attempting to bring a generic version of Novo Nordisk's GLP-1
agonist, marketed and sold as Wegovy for weight loss, and Ozempic for Type 2 diabetes, to
market. Wegovy has been earmarked to become one of the biggest selling drugs of all-time, so
it would be surprising if Viatris could successfully bring a generic version to market without
fighting a fierce legal campaign.
These court battles are part and parcel of any successful generic drug company's modus
operandi, however, so Viatris shareholders and prospective investors should probably get used
to such protracted legal disputes.
https://seekingalpha.com/article/4662767-viatris-2024-may-be-polarising-investment-opportunity-pharma?mailingid=33999913&messageid=mus… 8/11
15/01/2024, 09:16 Viatris In 2024 May Be The Most Polarising Investment Opportunity In Pharma (VTRS) _ Seeking Alpha
On the dermatology and gastrointestinal front, there has apparently been little progress, and
CEO Smith sounded somewhat evasive about the company's plans in these fields when
questioned during his recent fireside chat - the CEO was asked "I think you've mentioned
ophthalmology, dermatology, GI as kind of the big three, where of those three, do you see the
most opportunity for Viatris?" His reply is shared below:
So that's hard for me to answer directly, right. There's different types of opportunities in
those three buckets. I wouldn't say that one has way more opportunities than the other. I
think part of the reason that we were initially focused on those three areas, is we saw a lot of
opportunity in each of the three areas.
Again, there tends to be different types. It evolves over time, right, companies become more
viable in terms of business development, or transaction over time and less. So it's a very
dynamic situation. But we see all three of those therapeutic areas, I think, being very viable
in terms of our ability to partner, to license, to acquire assets.
In short, although Viatris has made some moves on the business development front, most
notably with its Oyster Point deal, management - both previous and current - has generally
proven itself to be much more adept at selling off chunks of the business than making bolt-on
acquisitions. The company will apparently net ~$3.6bn from the divestitures of its European
consumer health business, and women's health business in 2024 - it would be miraculous if the
company reinvests that money into M&A.
As such, although the outlook for the eye disease and generics businesses appears broadly
positive, it may not be enough to offset the slow erosion of legacy brands revenues, although it
may just be enough to keep shareholders happy in the short to medium term, with generous
dividend payouts and share buyback programs distracting them from the longer term issues.
Concluding Thoughts - As Mysterious As Ever, Viatris Is A
Polarising Stock That Is Complex To Value
Ultimately, Viatris defies valuation in many respects. It is difficult to value the company based
on top line revenues, as the main revenue contributing assets are expected to make smaller
and smaller contributions going forward - while management also appears ready and willing to
keep selling off assets, making it unclear whether Viatris' top line will ever experience growth.
It is tempting to wonder whether, if approached by another company and offered, let's say,
$17bn for all of its revenue generating assets, Viatris management would agree the deal, pay
off its debt, and share whatever is left with shareholders - that may be the optimal strategy for
valuing the business, in fact.
https://seekingalpha.com/article/4662767-viatris-2024-may-be-polarising-investment-opportunity-pharma?mailingid=33999913&messageid=mus… 9/11
15/01/2024, 09:16 Viatris In 2024 May Be The Most Polarising Investment Opportunity In Pharma (VTRS) _ Seeking Alpha
Essentially, the fact that the business is shrinking and heavily indebted is the key reason why
the business looks so undervalued based on a P/S ratio, or a price to free cash flow ratio, or
even when considering the generous dividend. A key question that needs answering is what
size Viatris will be in 5 years' time? Will it be a $5 - $10bn revenue company, but with <$10bn
debt, valued essentially the same as it is today?
FOLLOW US DOWNLOAD APP
That would be my conclusion at present - management inherited a complex, sprawling
business
Power towith a mixture of old and new assets, some promising, others simply a drain on
Investors
resources, a massive debt load, and a legacy brands business that provides an extremely
solid, if slowly shrinking, source of >$15bn per annum in top line revenues.
Subscription RSS Feed Sitemap Group Affiliate Program About Us Careers Contact Us
Support: 1- Subscriptions
The task has been to make the newer elements of the business work while maximising the
347-509-
revenue
6837 potential of the older assets all while paying down debt, and keeping investors happy.
Management has not pleased shareholders by consistently making business divestitures,
without showing that it has a clear plan to find new sources of revenues outside of complex
generics and eye care so far.
ACCOUNT STOCK ANALYSIS ANALYSIS BY SECTOR MARKET OUTLOOK MARKET NEWS
Essentially, if we subtract the ~$10bn per annum revenue contribution from the established
Account Settings Stock Ideas Energy Today's Market Top News
brands division in 2023 from the market cap valuation, we get $4bn, and then the question to
Create Portfolio Long Ideas Communication Economy Trending News
answer is whether Viatris without its established
Services brands is a business worth more or less than
Manage My Portfolio Stock Upgrades & Gold & Precious On the Move
that $4bn figure. We Downgrades
can arguably discount the debt from Metals
Real Estate this equation, as established brands
Privacy Market Pulse
revenues are profitable enough to support
Editor's Picks
successfully paying
Consumer Staples
down even such
Commodities
a large figure.
Alert Preferences Global Markets
Quick Picks & Lists Tech Forex
It is a tough question to answer, and my main concern is whether management willCalls
Notable be able to
findSUBSCRIPTIONS Emerging
assets that generate the Markets Basic Materials
kind of revenue streams andEditor's Picks that the established
profitability Buybacks
brands division
Premium & Pro
has, and still does. I think that could
Healthcare be an extremely
Cryptocurrency challenging goal for a
STOCK SCREENER Commodities
business busy paying down debt and keeping Consumer shareholders happy, but I also think that
Group Subscriptions MARKET DATA Cryptocurrency
shareholders and theStocksmarket may look Utilities
by Quant more favourably upon Viatris at the end of 2024 than at
Alpha Picks Debt/Share Issuance
the end of 2023, thanks to the cash earned
Top Stocks from the divestiture,
Financials Bond ETFsand the continuing strength of
Dividends - Stocks
established brands. Top Quant Dividend Industrials
INVESTING GROUPS Commodity ETFs
Stocks Dividends - Funds
Country ETFs
The short
Most term strength
Popular Highof the business
Dividend Yield - cash flow, revenue generation, dividend
STOCK COMPARISON Guidance - takes the
Currency ETFs
Stocks term fears around whether a globally successful generics business
attention away from longer
Free Trials TOOLS IPOs
Dividend ETFs
canTop
beRated
built on the ashes of Viagra, Lyrica, and Epi Pen, or whether more and
Top Dividend Stocks more
SPACs
FAANG Stocks Emerging Market
downsizing will be necessary going forward. For now at least, given the number
Dividend Investing of different of
Politics
ETFS & FUNDS ETFs
factors in play, I am happy to hold onto Gold
Value Investing
ETFs
my shares and wait for the picture to become clearer.
Global and Regional M&A
Gain access to all of the
ETF market
Screener Cash
research andEquivalents
financial analytics used in the preparation of this
Options Trading ETFs
US Economy
article plus exclusive ETF content and pharma,
Analysis healthcare
Big Bank Stocks and biotech investment
Growth vs. Value
Growth Stocks Wall Street Breakfast
recommendations and research / analytics by subscribing
Big Pharma Stocks ETFs
to my channel, Haggerston
ETF Guide
Biotech Investing
BioHealth. Mutual Funds Retail Stocks Market Cap ETFs
https://seekingalpha.com/article/4662767-viatris-2024-may-be-polarising-investment-opportunity-pharma?mailingid=33999913&messageid=mu… 10/11
15/01/2024, 09:16 Viatris In 2024 May Be The Most Polarising Investment Opportunity In Pharma (VTRS) _ Seeking Alpha
Tech Stocks Real Estate ETFs NEWS BY SECTOR
Closed End Funds
This article was written by TOP INDEXES
Quantitative Investing Sector ETFs
Editor's Picks Consumer
Edmund Ingham Dow Jones ETF Strategies
LEARN
10.64K Followers
Energy
DIVIDENDS S&P 500 Smart Beta
Financials
Edmund Ingham
Investing is a biotech consultant. He has been
Education Nasdaqcovering biotech, healthcare,
Themes &and pharma for over 5 years, and has
Dividend Stock News Healthcare
put together detailed reports of over 1,000 companies. He leads the investing Subsectors ETFs
group Haggerston BioHealth.
Investing Strategies Gold
REITs Tech
Show More Cryptocurrency
Retirement Investing Bitcoin
Dividend Ideas
Stock Market Sectors EARNINGS
Dividend Strategy
Analyst’s
StockDisclosure:
Market I/we have a beneficial long position in the shares of VTRS, OGN either through stock ownership, options, or other
derivatives. Dividend
Holidays & Hoursarticle myself,
I wrote this and Quick Picksmy own opinions. I am not receiving compensation for it (other
it expresses Earnings Calendar
than from Seeking
Alpha). I have no business relationship with any company whose stock is mentioned in this article.
After Hours Trading Editor's Picks Earnings News
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice Earnings
Portfolio is being given as to whether
Analysis
any Management
investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole.
Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts Earnings
are thirdCalls
party authors that
include both professional investors and individual investors who may not be licensed or certified by any institute orTranscripts
Cryptocurrency regulatory body.
Dividend Investing
Portfolio Strategy
Comments
Fixed Income (23)
Sort by Newest
Retirement
IPO's
Podcasts
Editor's Picks
Terms Of Use Privacy Do Not Sell My Personal Information Market Data Sources © 2024 Seeking Alpha
https://seekingalpha.com/article/4662767-viatris-2024-may-be-polarising-investment-opportunity-pharma?mailingid=33999913&messageid=mu… 11/11
